安帝君斯 AGEN 深 滬
等待開盤 01-28 09:30:00 美东时间
3.19
+0.170
+5.63%
華盛通- 最 高3.20
- 今 開3.03
- 成交量 51.01万股
- 最 低 3.00
- 昨 收 3.02
- 總市值 1.08亿
- 52周最高 7.34
- 市盈率 靜 --
- 換手率 1.50%
- 52周最低 1.38
- 委 比 -87.54%
- 總股本 3400.83万
- 歷史最高 202.5868
- 量 比 0.66
- 振 幅 6.62%
- 歷史最低 1.38
- 每 手 1
- 風險率 1.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Agenus Expands Global Medical Affairs Infrastructure And Early-Access Support Capabilities In Response To Increasing Physician-Initiated Interest Regarding Authorized Access To BOT+BAL
Medical Affairs scale-up supports France's multi-tumor AAC access framework and expanding paid named-patient programs requestsAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the
01-21 20:34
Agenus Expands Medical Affairs Infrastructure Amid Rising Demand for Botensilimab Access
Agenus Expands Medical Affairs Infrastructure Amid Rising Demand for Botensilimab Access Agenus Inc. has expanded its global Medical Affairs infrastructure to support growing physician interest in authorized access to its investigational immunotherapy combination, botensilimab plus balstilimab (BOT+
01-21 20:30
电话会总结 ｜ Agenus(AGEN)2024财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Agenus业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** 截至2024年第三季度末现金余额为4,480万美元，较2023年12月31日的7,610万美元大幅下降。季度结束后通过普通股销售额外筹集710万美元。 **营收表现：** 2024年第三季度营收2,500万美元，前九个月累计营收7,700万美元（包含非现金收入）。 **亏损情况：** 2024年第三季度净亏损6,700万美元，前九个月累计净亏损1.86亿美元，其中包含非现金运营费用分别为4,100万美元和1.12亿美元。 **现金流：** 2024年前九个
01-06 12:01
Agenus reports Q3 results
Agenus press release (AGEN): Q3 GAAP EPS of $1.94. Revenue of $30.2M (+20.3% Y/Y). More on Agenus Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript Agenus Inc. (AGEN) Virtual Stakeholder Briefing...
2025-11-10 20:37
Agenus Q3 EPS $1.94 Misses $1.98 Estimate, Sales $30.200M Miss $55.713M Estimate
Agenus (NASDAQ:AGEN) reported quarterly earnings of $1.94 per share which missed the analyst consensus estimate of $1.98 by 2.02 percent. This is a 162.99 percent increase over losses of $(3.08) per share from the same
2025-11-10 20:32
Insights Ahead: Agenus's Quarterly Earnings
Agenus (NASDAQ:AGEN) is set to give its latest quarterly earnings report on Mon...
2025-11-08 04:05
Agenus Releases New Data From Its botensilimab And balstilimab Combination Showing Durable Survival Benefits Across Multiple Late-Stage, Treatment-Resistant Cancers And That ~40% Of Patients With Very Limited Survival Expectation Are Alive At Two Years
Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastasesSignals of tumor agnostic benefit observedTumor types included CRC, sarcoma, ovarian, NSCLC,
2025-10-17 20:10
Agenus Secures $10M Promissory Note with Zydus
Agenus ( ($AGEN) ) has provided an update. On October 8, 2025, Agenus Inc. ente...
2025-10-10 04:30
Agenus Faces CFIUS Review Delay in Zydus Deal
Agenus ( ($AGEN) ) has provided an announcement. On June 3, 2025, Agenus and Zy...
2025-09-24 05:28
快讯 | Agenus公司 - 与Zydus Pharmaceuticals（美国）的交易完成时间推迟至2025年第四季度 - SEC文件
Agenus Inc - Closing of Deals With Zydus Pharmaceuticals (USA) Shifted to Q4 20...
2025-09-24 05:14
